Athersys Treatment for Stem Cell Transplant Complication Gets Orphan Status in … – Wall Street Journal
|
Athersys Treatment for Stem Cell Transplant Complication Gets Orphan Status in …
Wall Street Journal The biotechnology company said the designation complements the U.S. orphan drug status it received for its MultiStem therapy for patients at risk of developing graft-versus-host disease following hemoatopoietic stem cell transplants, which can be … Athersys’ MultiStem(R) Stem Cell Therapy Receives Orphan Drug Designation in …NASDAQ Athersys: EMA issues positive opinion on MultiStem Cell therapyRTT News |
